13F filer · CIK 1958125
Catalio Capital Management, LP
NEW YORK, NY · filing since Q4 2024 · last filing Sep 2, 2026
Reported value
$532.1M
+$53.4M vs prior
Positions
39
New / sold out
11 / 13
Added / reduced
15 / 8
Turnover
45.9%
buys $232.0M · sells $257.2M
Top-10 weight
56.7%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | AVALYN PHARMACEUTICALS INC | +1,675,830 | – | +$55.2M |
| New | JNJJOHNSON & JOHNSON | +138,946 | – | +$35.3M |
| New | PARABILIS MEDICINES INC | +824,043 | – | +$22.6M |
| Added | GILEAD SCIENCES INC | +105,404 | +64.3% | +$13.3M |
| New | PROTAGONIST THERAPEUTICS INC | +106,799 | – | +$13.1M |
| New | AXSOME THERAPEUTICS INC. | +43,182 | – | +$10.6M |
| New | KAILERA THERAPEUTICS INC | +468,750 | – | +$10.3M |
| New | ODYSSEY THERAPEUTICS INC | +457,839 | – | +$8.6M |
| New | ASCENDIS PHARMA A/S | +31,759 | – | +$8.5M |
| Added | SEPTERNA INC | +241,792 | +82.1% | +$8.1M |
16 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | DIANTHUS THERAPEUTICS INC | -527,367 | -94.1% | $-51.4M |
| Sold out | ASCENDIS PHARMA A/S | -129,111 | -100.0% | $-29.5M |
| Reduced | DEFINIUM THERAPEUTICS INC | -475,312 | -45.8% | $-22.4M |
| Sold out | TERNS PHARMACEUTICALS INC | -409,031 | -100.0% | $-21.6M |
| Sold out | SOLENO THERAPEUTICS INC | -577,808 | -100.0% | $-19.3M |
| Sold out | BOSTON SCIENTIFIC CORP | -299,318 | -100.0% | $-18.8M |
| Reduced | ULTRAGENYX PHARMACEUTICAL IN | -534,545 | -62.8% | $-17.8M |
| Reduced | VERADERMICS INC | -127,726 | -73.6% | $-15.7M |
| Sold out | CYTOKINETICS INC | -215,501 | -100.0% | $-14.2M |
| Sold out | ADAPTIVE BIOTECHNOLOGIES COR | -722,784 | -100.0% | $-10.0M |
11 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | AVALYN PHARMACEUTICALS INCCOM SHS | 1,675,830 | $55.2M | 10.37% |
| 2 | JNJJOHNSON & JOHNSON | 138,946 | $35.3M | 6.63% |
| 3 | GILEAD SCIENCES INCCOM | 269,309 | $34.0M | 6.39% |
| 4 | BRIDGEBIO PHARMA INCCOM | 455,041 | $33.9M | 6.37% |
| 5 | SYNDAX PHARMACEUTICALS INCCOM | 1,215,698 | $26.6M | 4.99% |
| 6 | DEFINIUM THERAPEUTICS INCCOM SHS | 562,672 | $26.5M | 4.97% |
| 7 | BRISTOL-MYERS SQUIBB COCOM | 412,961 | $23.8M | 4.47% |
| 8 | PARABILIS MEDICINES INCCOM | 824,043 | $22.6M | 4.24% |
| 9 | NATERA INCCOM | 82,181 | $22.3M | 4.19% |
| 10 | INCYTE CORPCOM | 191,627 | $21.7M | 4.08% |
29 more rows. Subscribe for $29/month to see every row, download the data and use the API.